Salt and polymorph selection strategy based on the biopharmaceutical classification system for early pharmaceutical development

American Pharmaceutical Review

Volumn 13, Issue 1, 2010, Pages 22-30

  Ku, M Sherry ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHLORIDE;

ARTICLE; BIOEQUIVALENCE; BIOPHARMACEUTICS CLASSIFICATION SYSTEM; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DESIGN; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; HIGH THROUGHPUT SCREENING; MOLECULAR MODEL; STOICHIOMETRY; THERMODYNAMICS; X RAY DIFFRACTION;

EID: 77649206778     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Amidon G. L., Lennernas H., Shah V. P., and Crison J. R. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12(1995) 413-420.
2. "Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral dosage Forms Based on a Biopharmaceutics Classification System", Food and Drug Administration, Rockville, MD, 2000.
3. Wu Chi-Yuan and Benet, Leslie Z. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System. Pharm. Res. 22(2005)11-23.
4. Kerns E. H., Di L. Multivariate pharmaceutical profiling for drug discovery. Curr. Top. Med. Chem. 2(2002)87-98.
5. Byrn, S. et al "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharm. Res., 12(1995) 945-954.
6. Chemburkar S.R., Bauer J., Deming K., Spiwek H., Patel K., Morris J., Henry R., Spanton S., Dziki W., Porter W., Quick J., Bauer P., Donaubauer J., Narayanan B.A., Soldani M., McFarland D., McFarland K., Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development, Org. Process Res. Dev. 4(2000) 413-417.
7. Ruffolo, R. R., R&D Productivity: A New Way of Working At Wyeth, American Pharmaceutical Review, Volume 7, June 2004.
8. Lipinski C.A., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 23 (1997) 3-25.
9. Lindenberg M., Kopp S., and Dressman J. B., Classification of orally administered drugs on the World Health Organization Model of Essential Medicines according to the Biopharmaceutics classification system, Eur. J. Pharm. Biopharm. 58(2004)265-278.
10. Ku M.S., An oral formulation decision tree based on the biopharmaceutical classification system for first in human clinical trials. Bulletin Technique Gattefosse 99 (2006):89-102.
11. Lipinski C.A., Poor aqueous solubility - an industry wide problem in drug discovery, Am. Pharm. Rev. 5 (3) (2002) 82-85.
12. Venkatesh S., Lipper R.A., Role of the development scientist in compound lead selection and optimization, J. Pharm. Sci. 89 (2000) 145-154.
13. Bighley L.D., Berge S.M., Monkhouse D.C., Salt forms of drugs and absorption, in: Swarbrick J., Boylan J.C. (Eds.), Encyclopedia of Pharmaceutical Technology 13,Marcel Dekker, New York, 1995, pp. 453-499.
14. Yoshioka S., Stella V.J., Stability of Drugs and Dosage Forms, Kluwer Academic Publishers, Plenum Publishers, NY, 2000.
15. Guillory J.K., Poust R.I., Chemical kinetics and drug stability, in: Banker G.S., Rhodes C.T. (Eds.), 4th ed., Modern Pharmaceutics. Drugs and the Pharmaceutical Sciences 121, Marcel Dekker, New York, NY, 2002, pp. 139-166 Revised and expanded.
16. "Guidance for Industry, ANDAs: Pharmaceutical Solid Polymorphism", draft, Food and Drug Administration, Rockville, MD, 2007.
17. International Conference on Harmonization Q6A Guideline. Specifications for New Drug substances and Products: Chemical Substances, 1999 October.
18. Kwong, E.,"PAT Implementation Strategies for Pharmaceuticals -IQPC April 11-13, 2007.
19. Lang M.D., Grzesiak A.L., Matzger A.J., The use of polymer heteronuclei for crystalline polymorph selection, J. Am. Chem. Soc. 124 (2002) 14834-14835.
20. Morissette S.L., Almarsson Örn, Peterson M.L., Remenar J.F., Read M.J., Lemmo A.V., Ellis S., Cima M.J., Gardner C.R.. Highthroughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Advanced Drug Delivery Reviews 56 (2004) 275-300
21. Almarsson, O., Gardner C.R., Novel approaches to issues of developability, January 2003, 21-26. http://www.currentdrugdiscovery.com
22. Ku M.S., Use of the Biopharmaceutical Classification System in Early Drug Development. The AAPS Journal 10 (2008) 208-12.
23. Price, SL, The computational prediction of pharmarceutical crystal structures and polymorphism. Advanced Drug Delivery Reviews 56 (23): 301-319, 2004